A preliminary pharmacokinetic study of liposomal leuprolide dry powder inhaler: A technical note

AAPS PharmSciTech

Volumn 6, Issue 3, 2005, Pages

  Shahiwala, Aliasgar ^a   Misra, Ambikanandan ^a  

^a M S UNIVERSITY OF BARODA   (India)

Author keywords

Dry powder inhaler; Leuprolide acetate; Liposome; Pharmacokinetics; Pulmonary

Indexed keywords

LEUPRORELIN; LUTEINIZING HORMONE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION COEFFICIENT; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG HALF LIFE; DRUG SYNTHESIS; DRY POWDER; FEMALE; MALE; NONHUMAN; PARTICLE SIZE; RADIOIMMUNOASSAY; RAT; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

EID: 27744601939     PISSN: 15309932     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/pt060360     Document Type: Article

References (23)

1. Jiang G, Qiu W, Deluca PP. Preparation and in vitro/in vivo evaluation of insulin-loaded poly (acryloylhydroxyethyl starch)-PLGA composite microspheres. Pharm Res. 2003;20:452-459.
2. Hildebrand GE, Tack JW. Microencapsulation of peptides and proteins. Int J Pharm. 2000;196:173-176.
3. Haeckel S, Sachse S, Albayrak C, Müller RH. Preparation and characterization of insulin-loaded microcapsules produced by the induced phase separation method. In: Proceedings of the World Meeting, Association of Industrial Galenique Pharmacy/Association of Primate Veterinarians; May 25-28, 1998; Paris, France. 1998. 507-508.
4. Wall DA. Pulmonary absorption of peptides and proteins. Drug Deliv. 1995;2:1-20.
5. Stanley SD. Delivery of peptide and non-peptide drugs through the respiratory tract. Pharm Sci Tech Today. 1999;12:450-459.
6. Niven RW. Delivery of biotherapeutics by inhalation aerosol. Crit Rev Ther Drug Carrier Syst. 1995;12:151-231.
7. Patton JS, Trinchero P, Platz RM. Bioavailability of pulmonary delivered peptide and protein: interferon alpha, calcitonin and parathyroid hormones. J Control Release. 1994;28:79-85.
8. Edwards DA, Hanes J, Caponetti G, et al. Large porous particles for pulmonary drug delivery. Science, 1997;276:1868-1871.
9. Berelowitz M, Becker G. Inhaled insulin: clinical pharmacology and clinical study results. Respir Drug Deliv. 2000;7:151-154.
10. Clauson PG, Balent B, Okikawa J, et al. PK-PD of four different doses of pulmonary insulin delivered with AERx Diabetes management system. Respir Drug Deliv. 2000;7:155-161.
11. Adjei A, Hui J, Finley R, Lin T, Fort F. Pulmonary bioavailability of leuprolide acetate following multiple dosing to beagle dogs: some pharmacokinetic and pre-clinical issues. Int J Pharm. 1994;107:57-66.
12. Garber RA, Cappelleri JC, Kourides IA, Gelgend RA, Chandler LP, Gorkin L. Improved patient satisfaction with inhaled insulin in subjects with Type I diabetes mellitus: results from a multi-center randomized controlled trial. Diabetes. 1999;48:A13.
13. Ganderton D. Targeted delivery of inhaled drugs: current challenges and future trends. J Aerosol Med. 1999;12:3-8.
14. Wall DA. Pulmonary absorption of peptides and proteins. Drug Deliv. 1995:1-20. This appears to be the same as reference 4. If both are the same, please delete this reference and renumber the references that follow.]]
15. Saari M, Vidgren MT, Koskinen MO, Turjanmaa VMH, Nieminen MM. Pulmonary distribution and clearance of two beclomethasone liposome formulations in healthy volunteers. Int J Pharm. 1999;181:1-9.
16. Waldrep JC, Gilbert BE, Knight CM, et al. Pulmonary delivery of beclomethasone liposome aerosol in volunteers. Tolerance and safety. Chest. 1997;111:316-323.
17. Kimelberg HK, Mayhew EG. Properties and biological effects of liposomes and their uses in pharmacology and toxicology. CRC Crit Rev Toxicol. 1978;6:25-79.
18. Szoka F, Papahadjopoulos D. Liposomes: preparation and characterization. In: Knight CG, ed. Liposomes: From Physical Structure to Therapeutic Applications. New York, NY: Elsevier/North-Holland Biomedical Press; 1981:51-82.
19. Poznansky MJ, Juliano RL. Biological approaches to the controlled delivery of drugs: a critical review. Pharmacol Rev, 1984;36:277-336.
20. Knight CG. Liposomes: From Physical Structure to Therapeutic Application. New York, NY: Elsevier/North-Holland Biomedical Press; 1981.
21. Akwete LA, Hsu L. Leuprolide and other LH-RH analogues in stability and characterization of protein and peptide drugs: case histories. In: Wang YJ, Pearlman R, eds. Formation, Characterization, and Stability of Protein Drugs. New York, NY: Plenum Press; 1993:159-199.
22. Enna SJ, Schanker LS. Absorption of drugs from the rat lung. Am J Physiol. 1972;223:1227-1231.
23. Poulain FR, Allen L, Williams MC, Hamilton RL, Hawoood S. Effects of surfactant apolipoproteins on liposome structure: implications for tubular myelin formation. Am J Physiol. 1992;262:L730-L739.